» Articles » PMID: 23503624

Multidimensional Assessment and Tailored Interventions for COPD: Respiratory Utopia or Common Sense?

Overview
Journal Thorax
Date 2013 Mar 19
PMID 23503624
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The rising disease burden from chronic obstructive pulmonary disease (COPD) requires new approaches.

Method: We suggest an approach based around three elements: inflammometry and multidimensional assessment to identify therapeutic targets and case management to design and implement an individualised treatment programme based on these assessments.

Discussion: This tailored approach to treatment would maximise efficacy, limit cost and permit a better risk-benefit ratio of treatment. The advantages include the ability to add up the benefits of individual therapies leading to a cumulative therapeutic benefit that is greater than each individual therapy alone. We can now design a multifaceted inflammometry intervention for airway diseases based on targeting eosinophilic inflammation, non-eosinophilic pathways and systemic inflammation. COPD is a complex and challenging disease. The use of inflammometry and multidimensional assessment is necessary to identify relevant treatment targets and maximise the scope of therapy while limiting unnecessary use of drugs. An individualised programme of management can be designed and coordinated by using a case manager. This new approach may provide tangible benefits to people with COPD.

Citing Articles

Inflammatory profile of eosinophils in asthma-COPD overlap and eosinophilic COPD: a multi-omics study.

Sunata K, Miyata J, Kawashima Y, Konno R, Ishikawa M, Hasegawa Y Front Immunol. 2024; 15:1445769.

PMID: 39439801 PMC: 11493663. DOI: 10.3389/fimmu.2024.1445769.


Integrating hot topics and implementation of treatable traits in asthma.

Gibson P, McDonald V Eur Respir J. 2024; 64(6).

PMID: 39255992 PMC: 11618818. DOI: 10.1183/13993003.00861-2024.


Physical capacity and inactivity in obstructive airway diseases: a "can do, do do" analysis.

Urroz Guerrero P, Lewthwaite H, Gibson P, Clark V, Cordova-Rivera L, McDonald V ERJ Open Res. 2024; 10(4).

PMID: 39040591 PMC: 11261380. DOI: 10.1183/23120541.00108-2024.


The treatable traits of asthma in pregnancy: a clinical audit.

Duszyk K, McDonald V, Thomas D, Steel K, Gibson P ERJ Open Res. 2024; 10(3).

PMID: 38887677 PMC: 11181053. DOI: 10.1183/23120541.00748-2023.


First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases.

Amati F, Stainer A, Maruca G, De Santis M, Mangiameli G, Torrisi C Biomedicines. 2024; 12(5).

PMID: 38791009 PMC: 11117749. DOI: 10.3390/biomedicines12051047.


References
1.
Buist A, McBurnie M, Vollmer W, Gillespie S, Burney P, Mannino D . International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet. 2007; 370(9589):741-50. DOI: 10.1016/S0140-6736(07)61377-4. View

2.
Lee T, Chen C, Shen H, Chang N . Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci (Lond). 2008; 116(6):497-505. DOI: 10.1042/CS20080241. View

3.
Sin D, Paul Man S, Marciniuk D, Ford G, Fitzgerald M, Wong E . The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008; 177(11):1207-14. DOI: 10.1164/rccm.200709-1356OC. View

4.
McDonald V, Higgins I, Gibson P . Managing older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges. Drugs Aging. 2012; 30(1):1-17. DOI: 10.1007/s40266-012-0042-z. View

5.
Simpson J, Powell H, Boyle M, Scott R, Gibson P . Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2007; 177(2):148-55. DOI: 10.1164/rccm.200707-1134OC. View